(10) showed that the PD-L1 expression, TMB level and CD8+ T cell infiltration were all low in EGFR mutation positive patients with an immune inert phenotype in tumor cells, although this trial demonstrated in vitro that cells expressing EGFR mutations could significantly suppress immune cell activity, but the exact mechanism remains unclear. The gene discussed is CD8A; the disease is neoplasm.